Pharma firms pile pressure on the UK as Trump’s drug pricing order looms
The external view of an office of an astrazeneca -biofarmautic company.
Cfoto | Future Publishing | Getty Images
UK, investments and stopped drug pricing negotiations under the pressure of offering a better agreement to the global pharmaceutical companies that appeared on US President Donald Trump’s state visit to England.
Drug companies, UK officials, in the future of this month Trump’s most preferred nation (MFN) drug pricing under the order of a quick approach to a quick delivery date to pay more for drugs and improve competitive landscape.
However, with very little movement from the government so far, firms are withdrawing the plug for proposed investments in England, claiming that some analysts may be a negotiation tactical to increase the British support.
Invetec, Global Healthcare & Industrials Equation Research Analyst Jimmy Mucheterere said on Monday that “at this point is a negotiation tactic and we think that most of these companies will not completely move away and redesign their investments.” He said.
Since the new US administration took office, “production places, innovation and price are all discussed”, the health economist in Ing Research Dieriik Stadig, CNBC’ye E -Posta said.
The UK’s spokesman for the Science, Technology and Innovation Department, the UK is “one of the most attractive places to invest in the world”, but “more” to attract funds and innovation “more” acknowledged.
Pharma attracts the plug
Anglo-Swedish drug producer Astrazeneca On Friday, the Cambridge research site planned £ 200 million (271.37 million dollars) and paused as a deduction with government support, he paused this year’s last withdrawal from England.
Movement came two days after the USA Farm company LensKnown as the MSD in Europe, a research center of £ 1 billion in London has scrapped, the lack of competitiveness of the UK and the “valuation of innovative drugs.
ZEPBURN MAKER Hand Lilly He also said that he paused the investment to the UK laboratory while waiting for more clarity around the United Kingdom Life Sciences environment.
“They are working together to make sure they have a maximum impact on the Trump administration and that they are working together against other governments,” Muchechetere said, “Trump. He said.
“We think this is something we will see from all companies. They work together because they all benefit or all are hit at the same time.”
When Astrazaneca, Merck and Eli Lilly were contacted by CNBC, he refused to comment on Muchechetere’s coordinated action suggestions.
Stadig from Ing said that the pharmaceutical firms, who re -positioned investment strategies in response to Trump administration, seemed to be early injured, but could follow the case in other countries.
“Pharma companies will allocate some of their capital to the United States at the expense of investing in competitor geographies,” Stadig said. He said.
“Britain is the first practical case of this … At the same time, we see that various pharmaceutical companies direct the current capacity to the US, which can pose more threats to England and European economies.”
DRUG Pricing Dead Date Stalls
To present the Trump management, large pharmaceutical companies were given until September 29th. “Binding commitments” to reduce drug prices to the levels paid by other developed countries.
Trump has long lambed for a long time because he did not pay the same pricing as the United States for the drugs of European countries and could not invest in innovation.
The US President will arrive in England on Tuesday for a three -day state visit only months after the British and the US’s Trump administration has made the flagship trade agreement. The agreement depends on the development of “overall environment” for the sector, although the “preferential treatment” for drugs is outlined.
The British government marked life sciences as one of the eight priority sectors when he announced his industrial strategy earlier this year. However, the plan -specific plan crushed many things in the sector and Merck said that the UK has not made significant progress towards lack of investment in the life of life industry “on Wednesday.
Meanwhile, long -standing debates on drug pricing between pharmaceutical companies and the British government were torn apart last month without making a decision.
More questions about the investment view of the UK has emerged. On Wednesday, a report published by the British Pharmaceutical Industry Association (ABPI) showed that the British direct investment in the pharmaceutical sector (DYY) in the pharmaceutical sector (DYM) ranking fell from second to seventh in 2023.
“We are faced with the risk of losing other countries that make brave moves to attract international mobile investments without a more competitive environment for investment,” ABPI CEO Richard Torbett said last week. He said.
Alex Altmann, a partner of Lubbock Fine, a sworn -in financial advisors and business consultants, called on the United States to follow the US leadership to double overseas investments. The Trump administration called on global drug producers to support the US production and led to a lot of multibillion investments in recent months, including Pharma Giants. Novartis, Sanofi and Roche.
“The US government is working hard to earn investment in their countries. England should show some of the same driving.” He said.
It shows the number of new numbers from the UK Business and Trade Department (DBT). DYY Projects In the UK, 2024/25 fell to 1,375 in the tax year, fell from 1,555 at 2023/24.
However, Invetec said that Motechetere is still in a strong position to earn Pharma investment if the UK’s “world -class scientific base” and increases its game in negotiations.
“England is in a great position to do more research and win some of this work. They just have to play ball.” He said.
